Holen Sie sich die Stockscreener-App
38.74
0.43%
-0.0997
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
IDEAYA Biosciences Doses First Patient in Phase 3 Trial - grafa.com
Guggenheim raises Ideaya Biosciences stock price target on DLL3 data - Investing.com
Guggenheim raises Ideaya Biosciences stock price target on DLL3 data By Investing.com - Investing.com Canada
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma - PR Newswire
IDEAYA at wells fargo healthcare conference: darovasertib nears NDA By Investing.com - Investing.com Canada
Phase III path opens for Ideaya’s IDE-849 in DLL3 ADC horse race - BioWorld News
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Citizens upgrades Ideaya Biosciences stock rating on IDE849 progress By Investing.com - Investing.com Nigeria
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences - PR Newswire
Citizens upgrades Ideaya Biosciences stock rating on IDE849 progress - Investing.com
IDEAYA Biosciences Sets London R&D Day for Nov. 16 | IDYA Stock News - Stock Titan
Avoiding Lag: Real-Time Signals in (IDYA) Movement - Stock Traders Daily
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer - PR Newswire
IDEAYA Biosciences (IDYA) Slips 2.3% to $40.81 as Biotech Momentum FadesMomentum Factor - vinanet.vn
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Ideaya Biosciences stock hits 52-week high at 40.88 USD By Investing.com - Investing.com Nigeria
Ideaya Biosciences stock hits 52-week high at 40.88 USD - Investing.com
Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform (IDYA) - Seeking Alpha
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Eastern Progress
Great Lakes Advisors LLC Makes New Investment in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA (IDYA) Results Check: The EPS Result Is Below Expectation in Latest Trading; Shares Close 2.48% Higher for the Current SessionEarnings Miss Alert - Vinanet
symbol__ Stock Quote Price and Forecast - CNN
IDEAYA partners with Genentech on pancreatic cancer trial By Investing.com - Investing.com South Africa
IDEAYA partners with Genentech on pancreatic cancer trial - Investing.com
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer - PR Newswire
Bank of America Corp DE Has $31.39 Million Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences (IDYA) Cash Flow Statement - Moomoo
Walleye Capital LLC Buys Shares of 386,183 IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Baker Bros. Advisors (IDYA) reports 5.2% IDEAYA stake and capped warrants - Stock Titan
IDEAYA Biosciences (IDYA) Holds Near $37 as Bulls Eye Breakout Above $38.81 ResistanceVolume Breakout Ideas - Vinanet
J.P. Morgan Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $62 - Moomoo
IDEAYA Biosciences (IDYA) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
How (IDYA) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
IDEAYA Biosciences (NASDAQ:IDYA) Displays Perfect Technical Strength and Breakout Setup - ChartMill
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58 - Moomoo
IDEAYA Biosciences Inc (IDYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
IDEAYA Biosciences (NASDAQ:IDYA) Is In A Strong Position To Grow Its Business - Moomoo
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership - Yahoo Finance
IDEAYA Biosciences (NASDAQ:IDYA) Given New $59.00 Price Target at Truist Financial - MarketBeat
Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $59 - Moomoo
A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $48 to $60 - Moomoo
IDEAYA BIOSCIENCES, INC. : LEERINK PARTNERS CUTS TARGET PRICE TO $31 FROM $37 - Bitget
IDEAYA Biosciences 2Q 2026: Revenue $8.86M, EPS $(1.22) — 10-Q Summary - TradingView
IDEAYA Biosciences (NASDAQ: IDYA) reports $1.24B cash and rising R&D spend - stocktitan.net
IDEAYA Biosciences (NASDAQ:IDYA) Releases Quarterly Earnings Results, Misses Estimates By $0.16 EPS - MarketBeat
IDEAYA Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q2 Revenue $8.9M, vs. FactSet Est of $8.0M - marketscreener.com
IDEAYA Posts Q2 Loss as Cash Reaches $1.24 Billion | IDYA Stock News - Quiver Quantitative
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
IDEAYA Biosciences (IDYA) Stock Analysis: Unpacking a 51% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
IDEAYA Posts Q2 Loss as Cash Reaches $1.24 Billion - quiverquant.com
IDEAYA Biosciences (IDYA) Expected to Post Earnings on Monday - MarketBeat
Seven Fleet Capital Management LP Buys New Position in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
14 New IDEAYA Hires Granted Stock Options at $36.40 - Stock Titan
IDEAYA Biosciences, Inc. $IDYA Shares Sold by Redmile Group LLC - MarketBeat
SummitTX Capital L.P. Purchases New Holdings in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62 - Moomoo
IDEAYA initiates expansion phase for cancer drug IDE892 By Investing.com - Investing.com Canada
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers - PR Newswire
IDEAYA expands cancer trial after IDE892 reaches target exposure - Stock Titan
IDEAYA Biosciences Inc (IDYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
0.29%
4.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):